GlassScriptPhysician profile
Sarah M Jensen
NPI 1841685310
$3,390.37
in general payments reported to CMS, 2019-2025
34 companies · $682 in 2025
The $682 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $319 · 2021: $511 · 2022: $472 · 2023: $619 · 2024: $379 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $569.89 | 2021-2025 | Azstarys |
| Tris Pharma INC | $388.11 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $230.21 | 2019-2025 | Doc Band |
| Kaleo, INC. | $165.85 | 2022-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $159.85 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $156.98 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $154.36 | 2019-2024 | Cotempla Xr-Odt |
| Sobi, INC | $147.47 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $138.21 | 2022-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $126.60 | 2021-2025 | Pediarix, Bexsero, Rotarix |
| Noven Therapeutics, LLC | $122.73 | 2023-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $116.87 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $113.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.16 | 2021-2022 | |
| Abbvie INC. | $84.74 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.45 | 2020-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi-Aventis U.S. LLC | $68.23 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $67.29 | 2019 | |
| Azurity Pharmaceuticals, INC. | $50.56 | 2025 | Alvesco |
| Pfizer INC. | $43.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $39.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $32.34 | 2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $29.36 | 2021-2023 | |
| Seqirus USA INC | $28.49 | 2025 | Flucelvax |
| Genentech USA, INC. | $28.34 | 2019-2020 | |
| Baxter Healthcare | $28.25 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Astrazeneca Pharmaceuticals LP | $25.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $23.80 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $14.85 | 2022 | |
| Phadia US INC. | $14.73 | 2021 | |
| Qol Medical, LLC | $14.63 | 2021 | |
| Smith+Nephew, INC. | $13.95 | 2021 | |
| Biomarin Pharmaceutical INC. | $13.41 | 2024 | Voxzogo 1.2mg |
| Amneal Pharmaceuticals LLC | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.